ReviewFrontiers in nutrition2022
Advanced glycation end products in diabetic retinopathy and phytochemical therapy.
Review in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- Review
- AI-driven multimodal retinal imaging for early detection and risk stratification of vascular and neurodegenerative diseases.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- From Traditional Spice to Functional Ingredient: Phenolic Profile and Bioactive Properties of Sicilian Rhus coriaria L. Fruit.Chemistry & biodiversity · 2026Article
- Dysfunction of the Neurovascular Unit in Diabetic Retinopathy: Advances from Molecular Mechanisms to Targeted Interventions.Stem cell reviews and reports · 2026Review
- RBM15 promotes hyperglycemia-induced retinal endothelial cell injury by regulating FOXO3 stability via m6A modification.Molecular and cellular biochemistry · 2026Article
- Contrast Sensitivity Impairment in Diabetic Retinopathy: Clinical and Structural Correlates.Diagnostics (Basel, Switzerland) · 2026Review
- Editorial of Special Issue "Molecular Research and Recent Advances in Diabetic Retinopathy: Second Edition".Biomedicines · 2026Article
- Oxidative Stress in Diabetic Retinopathy: Pathogenic Mechanisms, Biomarkers and Clinical Implications.Antioxidants (Basel, Switzerland) · 2026Review
- Advanced Glycation End Products and Metabolic-Mechanical Coupling in Diabetic Retinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Adjunctive EGb 761 treatment in patients with Parkinson's disease: a case series.Frontiers in aging neuroscience · 2026Article
- Neurodegeneration as an early driver and therapeutic target in diabetic retinopathy.International journal of ophthalmology · 2026Review
- The diabetic retina-brain axis hypothesis in diabetic cognitive impairment: from pathophysiological mechanisms to therapeutic implications.Frontiers in endocrinology · 2026Review
- Development of a Glycated Albumin-Based Algorithm to Evaluate Diabetic Retinopathy in Adults with Type 2 Diabetes: A Cross-Sectional Study at a Hospital-Affiliated Physical Examination Center.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Multi-omics and experimental validation studies reveal key biomarkers of cellular senescence in diabetic retinopathy.Diabetology & metabolic syndrome · 2025Article
- Retinal Autophagy for Sustaining Retinal Integrity as a Proof of Concept for Age-Related Macular Degeneration.International journal of molecular sciences · 2025Review
- Genetic Correlation and Mendelian Randomization Analyses Support Causal Relationships Between Instant Coffee and Age-Related Macular Degeneration.Food science & nutrition · 2025Article
- The role of microglia in the development of diabetic retinopathy and its potential clinical application.Human cell · 2025Review
- High Ocular Disease Burden and Increased Referral Needs in Patients with Chronic Kidney Disease: A Step Toward Personalized Care.Journal of personalized medicine · 2025Article
- Effect of ranibizumab on diabetic retinopathyWorld journal of diabetes · 2025Article
- Circulating Cell-Free DNA as an Epigenetic Biomarker for Early Diabetic Retinopathy: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced glycation end products (AGEs) are generated by the nonenzymatic glycation of proteins or lipids. Diabetic retinopathy (DR) is one common complication in patients with diabetes. The accumulation of AGEs in retinal cells is strongly associated with the development of DR. AGEs can induce the breakdown of redox balance and then cause oxidative stress in retinal cells, exerting cytopathic effects in the progression of DR. The interaction between AGEs and the receptor for AGE (RAGE) is involved in multiple cellular pathological alterations in the retina. This review is to elucidate the pathogenetic roles of AGEs in the progression of DR, including metabolic abnormalities, lipid peroxidation, structural and functional alterations, and neurodegeneration. In addition, disorders associated with AGEs can be used as potential therapeutic targets to explore effective and safe treatments for DR. In this review, we have also introduced antioxidant phytochemicals as potential therapeutic strategies for the treatment of DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.